Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7802114 | 0.87 | KMT2A (0.55) | KDM4EPOLBCTNNB1WNT3AKMT2A | |
| SCHEMBL7800904 | 0.81 | NPC1 (0.50) | KDM4ECTNNB1WNT3AKMT2ANPC1 | |
| SCHEMBL7802113 | 0.81 | LMNA (0.43) | KDM4EKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL7799781 | 0.80 | RAB9A (0.50) | POLBCTNNB1WNT3AKMT2ANPC1 | |
| SCHEMBL8544701 | 0.79 | KMT2A (0.57) | POLBKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL7797675 | 0.79 | KMT2A (0.43) | KMT2ANPC1RAB9AEDNRBMEN1 | |
| SCHEMBL7801729 | 0.79 | KMT2A (0.57) | POLBKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL795101 | 0.78 | MAOB (0.50) | POLBKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL7801009 | 0.78 | LTB4R (0.47) | KDM4EPOLBCTNNB1WNT3AKMT2A | |
| SCHEMBL7791690 | 0.76 | ALDH1A1 (0.50) | KDM4EKMT2ANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010014694-A1 | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS, INC. | 2001-08-16 | — | — | US | disclosed |
| US-6265428-B1 | VASODILATION | TEXAS BIOTECHNOLOGY CORPORATION | 2001-07-24 | — | — | US | disclosed |
| US-5977117-A | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014694-A1 | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, NPR1 | KDM4E 1955/4885POLB 3419/4885CTNNB1 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.